Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | FABP7 | O15540 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30570803 | 1.00 | KMT2A (0.63) | KMT2AEPHX2OPRD1CASP3FABP7 | |
| SCHEMBL6032374 | 0.91 | KMT2A (0.67) | KMT2AEPHX2OPRD1CASP3FABP7 | |
| SCHEMBL14247589 | 0.88 | KMT2A (0.60) | KMT2AEPHX2OPRD1CASP3FABP7 | |
| SCHEMBL30640436 | 0.88 | KMT2A (0.59) | KMT2AEPHX2OPRD1CASP3FABP7 | |
| SCHEMBL525564 | 0.88 | KMT2A (0.59) | KMT2AEPHX2OPRD1CASP3FABP7 | |
| SCHEMBL5963770 | 0.84 | KMT2A (0.47) | KMT2ACASP3 | |
| SCHEMBL23270799 | 0.84 | KMT2A (0.62) | KMT2AEPHX2OPRD1HDAC3HDAC4 | |
| SCHEMBL8013815 | 0.82 | KMT2A (0.69) | KMT2A | |
| SCHEMBL29679600 | 0.82 | EPHX2 (0.60) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL1001375 | 0.82 | EPHX2 (0.60) | KMT2AEPHX2CASP3FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753447-B2 | Cyclic peptides, methods of synthesis, and methods of treatment | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753447-B2 | Cyclic peptides, methods of synthesis, and methods of treatment | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-09-12 | — | — | US | disclosed |
| US-20220033444-A1 | Cyclic Peptides, Methods of Synthesis, and Methods of Treatment | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-03 | — | — | US | disclosed |
| EP-3362454-A1 | EP4 ANTAGONISTS | Eisai R&D Management Co., Ltd. (JP) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017066633-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753447-B2 | Cyclic peptides, methods of synthesis, and methods of treatment | VIP, PTMS, SARS1 | KMT2A 4793/4885EPHX2 4199/4885OPRD1 2438/4885 |
| US-20220033444-A1 | Cyclic Peptides, Methods of Synthesis, and Methods of Treatment | VIP, PTMS, SARS1 | KMT2A 4793/4885EPHX2 4199/4885OPRD1 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.